Market Overview

UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

Share:
Related CPHD
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
Benzinga's Top Downgrades

Bank of America initiated coverage on Cepheid (NASDAQ: CPHD) with a Buy rating and a $40 price objective.

Bank of America noted, "With one of the largest available test menus and more on the way, CPHD's prospects for increasing its installed base and reagent pull-through is positive, as it will become increasingly difficult for customers to justify supporting multiple platforms that run a limited number of tests. As more labs convert to MDx testing, we see CPHD as well positioned to grow. Moreover, our checks suggest that CPHD should see some success as it engages the MDx heavyweights in more established segments of the market (eg, CT/NG)."

Cepheid closed at $32.63 on Friday.

Latest Ratings for CPHD

DateFirmActionFromTo
Sep 2016BairdDowngradesOutperformNeutral
Sep 2016CitigroupDowngradesBuyNeutral
Sep 2016Cowen & Co.DowngradesOutperformMarket Perform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (CPHD)

View Comments and Join the Discussion!